News

Wright joins Schroer for a discussion on updates in pediatric eosinophilic esophagitis at AAAAI 2026.

New data reveal who misses oral food challenges despite scheduling, spotlighting race and insurance gaps—and the barriers clinics can fix.

The expanded approval provides young pediatric patients with a proven, effective treatment to significantly reduce dangerously high LDL-C levels.

Brian Schroer, MD, highlights recent data exploring the origins of EoE inflammation and the efficacy and limitations of recent biologic treatments.

UCB leadership discusses how bridging regulatory approval and real-world access requires integrated care coordination and a long-term commitment to the patient journey.

Carissa Baker-Smith, MD, MPH, outlines practical office-based interventions to help pediatricians effectively manage youth cardiovascular risk factors.

The approval offers a new genotype-independent treatment option for patients aged 12 years and older, significantly reducing blood phenylalanine levels.

Carissa M. Baker-Smithm MD, MPH, outlines how pediatricians can mitigate long-term cardiovascular risk.

Hao Zhang, PhD, MPH, and Biaskha “Pia” Sen, PHD, discuss factors contributing to the rise in pediatric diabetes rates.

David Fleischer, MD, discusses how the VITESSE trial positions the VIASKIN peanut patch as a promising option for children with peanut allergy.

Early identification of X-linked hypophosphatemia can prevent long-term skeletal deformities and improve outcomes through timely initiation of targeted therapy.

FDA okays once-weekly navepegritide for children with achondroplasia, boosting growth with strong trial data; rollout expected early Q2 2026.

The FDA has approved once-weekly somapacitan-beco for children aged 2.5 years and older with 3 separate growth indications.

A study found that hepatitis B virus birth dose vaccination rates fell from 83.5% in early 2023 to 73.2% by August 2025.

Druhan L. Howell, MD, discusses how new data on once-daily tapinarof show early, sustained improvements in itch and sleep outcomes.

A study found that cannabis use was associated with a doubled risk of psychotic and bipolar disorders.

The FDA has approved desmopressin acetate, the first formulation designed for individualized dosing in patients with central diabetes insipidus.

Christopher J. Romero, MD, outlines practical, patient-centered strategies for navigating evolving parent and adolescent preferences in pediatric growth hormone deficiency.

Jolanta Bernatoniene, MD, PhD, discusses data showing oral berotralstat significantly reduces moderate and severe attacks in children with hereditary angioedema.

The approval marks the first FDA-authorized treatment for allergic fungal rhinosinusitis, with trial data showing significant improvements in outcome measures.

From 2010 to 2022, urban hospitals expanded access to advanced neonatal services while rural communities experienced a net loss.

A study found cannabis use among adolescents aged 13 to 17 years was associated with a 2-fold increased risk of psychotic and bipolar disorders.

Although early introduction of allergenic foods remains a key strategy for preventing food allergies, rising infant emergency department visits may reflect mild, manageable reactions and uncertainty among families.

Suicide rates and attempts among Black youth have surged over the past decade, highlighting critical risk factors and the need for proactive screening and community-based prevention strategies.

New research highlights the fluctuating course of pediatric ADHD and the continued role of stimulant medications as first-line therapy.

A study highlights prior self-harm, traumatic brain injury, family instability, and social vulnerability as major risk factors associated with suicide among Black youth.

The gadopiclenol extension for use in infants and neonates offers high-quality MRI contrast enhancement at half the standard gadolinium dose.

National survey data show a 35% increase in child mental health conditions since 2016, with one-fourth of households reporting unmet treatment needs.